Advertisement
Table 1 Comparison of Baseline Demographic and Clinical Characteristics by Region
| Region | |||||
|---|---|---|---|---|---|
| Characteristics | Total (n = 3648) | BC (n = 1674) | Ontario (n = 1143) | Quebec (n = 831) | p value |
| Age | 40 (34-46) | 40 (34-47) | 39 (34-45) | 40 (34-46) | < 0.01 |
| Male | 2925 (80%) | 1328 (79%) | 934 (82%) | 663 (80%) | 0.28 |
| Race† | |||||
| Caucasian | 956 (52%) | 552 (45%) | 309 (50%) | 95 (84%) | < 0.0001 |
| Black | 181 (10%) | 31 (3%) | 138 (26%) | 12 (11%) | |
| First Nation | 121 (7%) | 103 (9%) | 15 (3%) | 3 (3%) | |
| Mixed | 465 (25%) | 464 (38%) | 1 (<% | 0 (0%) | |
| Other | 128 (7%) | 66 (5%) | 59 (11%) | 3 (3%) | |
| Missing | 1837 | 497 | 622 | 718 | |
| Risk factor‡ | |||||
| MSM | 1015 (34%) | 203 (12%) | 362 (66%) | 450 (60%) | < 0.0001 |
| IDU | 632 (21%) | 442 (26%) | 82 (13%) | 108 (14%) | < 0.0001 |
| Heterosexual | 486 (16%) | 98 (6%) | 188 (35%) | 200 (27%) | < 0.0001 |
| Endemic country | 233 (19%) | 0 (0%) | 92 (20%) | 141 (19%) | 0.52 |
| Blood product recipient | 43 (1%) | 10 (1%) | 25 (6%) | 8 (1%) | < 0.0001 |
| Other/Missing | 1554 (43%) | 961 (57%) | 569 (45%) | 147 (9%) | < 0.0001 |
| AIDS defining illness | 481 (13%) | 259 (15%) | 115 (10%) | 107 (13%) | < 0.001 |
| cART initiation date | 2003 (2001-05) | 2003 (2001-05) | 2004 (2002 - 05) | 2004 (2002-05) | < 0.0001 |
| Type of cART | |||||
| NNRTI-based | 1586 (43%) | 753 (45%) | 512 (45%) | 321 (39%) | < 0.0001 |
| Boosted PI-based | 1433 (39%) | 726 (43%) | 397 (35%) | 310 (37%) | |
| Single PI-based | 384 (11%) | 151 (9%) | 137 (12%) | 96 (12%) | |
| Other cART | 245 (7%) | 44 (3%) | 97 (8%) | 104 (13%) | |
| CD4 count (cells/mm3) | 190 (100-277) | 170 (80-260) | 202 (107-296) | 208 (127-290) | < 0.0001 |
| CD4 count category | |||||
| < 200 cells/mm3 | 1921 (53%) | 981 (59%) | 555 (49%) | 385 (47%) | < 0.0001 |
| 200 - 350 cells/mm3 | 1175 (32%) | 486 (29%) | 374 (33%) | 315 (38%) | |
| > 350 cells/mm3 | 544 (15%) | 207 (12%) | 212 (19%) | 125 (15%) | |
| VL (log10 copies/mL) | 4.9 (4.4-5.1) | 5.0 (4.6-5.0) | 4.8 (4.3-5.3) | 4.8 (4.2-5.2) | < 0.01 |
| VL <50 copies/mL | 139 (4%) | 56 (3%) | 48 (4%) | 35 (4%) | 0.40 |
| Hepatitis C co-infection | 736 (30%) | 501 (44%) | 124 (22%) | 111 (15%) | < 0.0001 |
